BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27636548)

  • 21. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
    Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
    J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia.
    Niavarani A; Horswell S; Sadri R; Bonnet D
    Ann Hematol; 2016 Jan; 95(2):179-90. PubMed ID: 26499507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Del (9q) AML: clinical and cytological characteristics and prognostic implications.
    Peniket A; Wainscoat J; Side L; Daly S; Kusec R; Buck G; Wheatley K; Walker H; Chatters S; Harrison C; Boultwood J; Goldstone A; Burnett A
    Br J Haematol; 2005 Apr; 129(2):210-20. PubMed ID: 15813849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
    Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
    Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
    Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
    Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.
    Shin SY; Lee ST; Kim HJ; Cho EH; Kim JW; Park S; Jung CW; Kim SH
    Oncotarget; 2016 Aug; 7(34):54825-54837. PubMed ID: 27359055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Features of Interstitial Deletions of Chromosome 9q in Acute Myeloid Leukemia.
    Qi Z; Wen KW; Ki A; Prakash S; Kogan S; Yu J
    Cytogenet Genome Res; 2022; 162(3):119-123. PubMed ID: 35675801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
    Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
    Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two Novel Mutations of the NPM1 Gene in Syrian Adult Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Alarbeed IF; Wafa A; Moassass F; Al-Halabi B; Alachkar W; Aboukhamis I
    Asian Pac J Cancer Prev; 2021 Jan; 22(1):227-232. PubMed ID: 33507703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
    Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications of
    Tan M; Ng IKS; Chen Z; Ban K; Ng C; Chiu L; Seah E; Lin M; Tai BC; Yan B; Ng CH; Chng WJ
    J Clin Pathol; 2017 Aug; 70(8):669-676. PubMed ID: 28100593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.
    Yamato G; Yamaguchi H; Handa H; Shiba N; Kawamura M; Wakita S; Inokuchi K; Hara Y; Ohki K; Okubo J; Park MJ; Sotomatsu M; Arakawa H; Hayashi Y
    Genes Chromosomes Cancer; 2017 Nov; 56(11):800-809. PubMed ID: 28710806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
    Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
    Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.